Propeller Health’s Digital Health Platform Cleared for Use with Symbicort Inhaler

Propeller Health’s digital health tool has received an additional clearance from the FDA, allowing it to be used to collect data from patients using AstraZeneca’s Symbicort inhaler.

The system is designed to help patients manage their asthma and chronic obstructive pulmonary disease (COPD). It uses sensors to analyze a patient’s inhaler use and sends the data to the company’s Propeller smartphone app, which patients can then share with clinicians.

The platform was previously cleared to connect to many other inhalers used by asthma and COPD patients, including products made by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion.